Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 412

2.

Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair.

Forster R, Stewart M.

Cochrane Database Syst Rev. 2016 Mar 30;3:CD004179. doi: 10.1002/14651858.CD004179.pub2. Review.

PMID:
27027384
3.

Anaesthesia for hip fracture surgery in adults.

Guay J, Parker MJ, Gajendragadkar PR, Kopp S.

Cochrane Database Syst Rev. 2016 Feb 22;2:CD000521. doi: 10.1002/14651858.CD000521.pub3. Review.

PMID:
26899415
4.

Comparison of thromboprophylaxis patterns in arthroplasty in public and private hospitals.

Cortada AP, Silva TG, Silva AC, Golmia RP, Guerra RL, Takemoto ML, Monteiro RD, Scheinberg MA.

Einstein (Sao Paulo). 2015 Jul-Sep;13(3):410-6. doi: 10.1590/S1679-45082015GS3057. Epub 2015 Aug 25. English, Portuguese.

5.

Comparison of switch-therapy modalities (enoxaparin to rivaroxaban/dabigatran) and enoxaparin monotherapy after hip and knee replacement.

Özler T, Uluçay Ç, Önal A, Altıntaş F.

Acta Orthop Traumatol Turc. 2015;49(3):255-9. doi: 10.3944/AOTT.2015.14.0219.

6.

What's New in Venous Thromboembolic Prophylaxis Following Total Knee and Total Hip Arthroplasty? An Update.

Pierce TP, Elmallah RK, Jauregui JJ, Cherian JJ, Mont MA.

Surg Technol Int. 2015 May;26:234-7. Review.

PMID:
26055015
7.

Post-operative arterial thrombosis with non-vitamin K antagonist oral anticoagulants after total hip or knee arthroplasty.

Squizzato A, Lussana F, Cattaneo M.

Thromb Haemost. 2015 Aug;114(2):237-44. doi: 10.1160/TH15-01-0073. Epub 2015 May 7. Review.

PMID:
25946985
8.

Clinical experience with novel oral anticoagulants for thromboprophylaxis after elective hip and knee arthroplasty.

Messerschmidt C, Friedman RJ.

Arterioscler Thromb Vasc Biol. 2015 Apr;35(4):771-8. doi: 10.1161/ATVBAHA.114.303400. Epub 2015 Mar 12. Review.

9.

Venous thromboembolism rates in patients undergoing major hip and knee joint surgery at Waitemata District Health Board: a retrospective audit.

Dixon J, Ahn E, Zhou L, Lim R, Simpson D, Merriman EG.

Intern Med J. 2015 Apr;45(4):416-22. doi: 10.1111/imj.12702.

PMID:
25644232
10.

Incidence of symptomatic venous thromboembolism in patients with hemophilia undergoing joint replacement surgery: a retrospective study.

Perez Botero J, Spoon DB, Patnaik MS, Ashrani AA, Trousdale RT, Pruthi RK.

Thromb Res. 2015 Jan;135(1):109-13. doi: 10.1016/j.thromres.2014.11.010. Epub 2014 Nov 18.

PMID:
25434629
11.

Deep-vein thrombosis prophylaxis in foot and ankle surgery: what is the current state of practice?

Shah K, Thevendran G, Younger A, Pinney SJ.

Foot Ankle Spec. 2015 Apr;8(2):101-6. doi: 10.1177/1938640014546858. Epub 2014 Sep 8.

PMID:
25205678
12.

[Effects of batroxobin on perioperative blood loss and coagulation in patients with low molecular weight heparin when undergoing the total hip replacement].

Ding G, Li S, Pan Z, Gao C, Ma H.

Zhonghua Liu Xing Bing Xue Za Zhi. 2014 Jun;35(6):737-40. Chinese.

PMID:
25174484
13.

Fatal intrahepatic hemorrhage after nadroparin use for total hip arthroplasty.

Ventura F, Bonsignore A, De Stefano F, Pizzorno E, Palmiere C.

Forensic Sci Med Pathol. 2014 Dec;10(4):619-22. doi: 10.1007/s12024-014-9593-0. Epub 2014 Aug 10.

PMID:
25108423
14.

Rivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort study.

Lazo-Langner A, Fleet JL, McArthur E, Garg AX.

J Thromb Haemost. 2014 Oct;12(10):1626-35. doi: 10.1111/jth.12675. Epub 2014 Aug 26.

PMID:
25069387
15.

Venous thromboembolism after total joint arthroplasty: results from a Japanese multicenter cohort study.

Migita K, Bito S, Nakamura M, Miyata S, Saito M, Kakizaki H, Nakayama Y, Matsusita T, Furuichi I, Sasazaki Y, Tanaka T, Yoshida M, Kaneko H, Abe I, Mine T, Ihara K, Kuratsu S, Saisho K, Miyahara H, Segata T, Nakagawa Y, Kamei M, Torigoshi T, Motokawa S.

Arthritis Res Ther. 2014 Jul 21;16(4):R154. doi: 10.1186/ar4616.

16.

Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan.

Fuji T, Wang CJ, Fujita S, Kawai Y, Kimura T, Tachibana S.

J Arthroplasty. 2014 Dec;29(12):2439-46. doi: 10.1016/j.arth.2014.05.029. Epub 2014 Jun 9.

17.

Changes of thrombelastography in patients undergoing elective primary total knee and total hip replacement with low molecular heparin prophylaxis.

Yang Y, Yao Z, Dai W, Shi P, Luo L, Zhang C.

J Orthop Surg Res. 2014 Jul 8;9:52. doi: 10.1186/s13018-014-0052-0.

18.

Indirect comparison meta-analysis of two enoxaparin regimens in patients undergoing major orthopaedic surgery. Impact on the interpretation of thromboprophylactic effects of new anticoagulant drugs.

Laporte S, Chapelle C, Bertoletti L, Lega JC, Cucherat M, Zufferey PJ, Darmon JY, Mismetti P; META-EMBOL Group.

Thromb Haemost. 2014 Sep 2;112(3):503-10. doi: 10.1160/TH14-01-0064. Epub 2014 Jun 26.

PMID:
24965841
19.

Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty.

Levitan B, Yuan Z, Turpie AG, Friedman RJ, Homering M, Berlin JA, Berkowitz SD, Weinstein RB, DiBattiste PM.

Vasc Health Risk Manag. 2014 Mar 26;10:157-67. doi: 10.2147/VHRM.S54714. eCollection 2014.

20.

Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity.

Robertson L, Roche A.

Cochrane Database Syst Rev. 2013 Dec 16;(12):CD010525. doi: 10.1002/14651858.CD010525.pub2. Review.

PMID:
24343728
Items per page

Supplemental Content

Loading ...
Write to the Help Desk